Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Restricted access

The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although certain lesions can be treated with margin-negative local excision alone. Disease surveillance is recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is essential for optimal patient care.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Anal Carcinoma Panel are not printed in this issue of JNCCN but can be accessed online at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Anal Carcinoma Panel

At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Anal Carcinoma Panel members can be found on page 871. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)

These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

NCCN Anal Carcinoma Panel Members

*Al B. Benson III, MD/Chair†

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

*Alan P. Venook, MD/Vice-Chair†‡

UCSF Helen Diller Family Comprehensive Cancer Center

Mahmoud M. Al-Hawary, MDф

University of Michigan Rogel Cancer Center

Lynette Cederquist, MDÞ

UC San Diego Moores Cancer Center

Yi-Jen Chen, MD, PhD§

City of Hope Comprehensive Cancer Center

Kristen K. Ciombor, MD†

Vanderbilt-Ingram Cancer Center

Stacey Cohen, MD†

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Harry S. Cooper, MD≠

Fox Chase Cancer Center

Dustin Deming, MD†

University of Wisconsin Carbone Cancer Center

Paul F. Engstrom, MD†

Fox Chase Cancer Center

Jean L. Grem, MD†

Fred & Pamela Buffett Cancer Center

Axel Grothey, MD†

Mayo Clinic Cancer Center

Howard S. Hochster, MD†

Yale Cancer Center/Smilow Cancer Hospital

Sarah Hoffe, MD§

Moffitt Cancer Center

Steven Hunt, MD¶

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Ahmed Kamel, MDф

University of Alabama at Birmingham Comprehensive Cancer Center

Natalie Kirilcuk, MD¶

Stanford Cancer Institute

Smitha Krishnamurthi, MD†Þ

Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Wells A. Messersmith, MD†

University of Colorado Cancer Center

Jeffrey Meyerhardt, MD, MPH†

Dana-Farber Cancer Institute

Mary F. Mulcahy, MD‡†

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

James D. Murphy, MD, MS§

UC San Diego Moores Cancer Center

Steven Nurkin, MD, MS¶

Roswell Park Comprehensive Cancer Center

Leonard Saltz, MD†‡Þ

Memorial Sloan Kettering Cancer Center

Sunil Sharma, MD†

Huntsman Cancer Institute at the University of Utah

David Shibata, MD¶

St. Jude Children's Research Hospital/The University of Tennessee Health Science Center

John M. Skibber, MD¶

The University of Texas MD Anderson Cancer Center

Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSEф

Memorial Sloan Kettering Cancer Center

Elena M. Stoffel, MD, MPH¤

University of Michigan Rogel Cancer Center

Eden Stotsky-Himelfarb, BSN, RN¥

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Christopher G. Willett, MD§

Duke Cancer Institute

Evan Wuthrick, MD§

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

NCCN Staff: Deborah A. Freedman-Cass, PhD, and Kristina M. Gregory, RN, MSN, OCN

*Discussion Section Writing Committee

Specialties: †Medical Oncology; §Radiotherapy/Radiation Oncology; ¶Surgery/Surgical Oncology; ≠Pathology; ‡Hematology/Hematology Oncology; ÞInternal Medicine; фDiagnostic/Interventional Radiology; ¤Gastroenterology; ¥Patient Advocate

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:730.

  • 2.

    Jemal A, Simard EP, Dorell C. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175201.

    • Search Google Scholar
    • Export Citation
  • 3.

    Johnson LG, Madeleine MM, Newcomer LM. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281288.

    • Search Google Scholar
    • Export Citation
  • 4.

    Nelson RA, Levine AM, Bernstein L. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol 2013;31:15691575.

  • 5.

    Shiels MS, Kreimer AR, Coghill AE. Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomarkers Prev 2015;24:15481556.

    • Search Google Scholar
    • Export Citation
  • 6.

    Glynne-Jones R, Nilsson PJ, Aschele C. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 2014;111:330339.

    • Search Google Scholar
    • Export Citation
  • 7.

    Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000;342:792800.

  • 8.

    Cummings BJ, Ajani JA, Swallow CJ. Cancer of the anal region. In: DeVita VT, Lawrence TS, Rosenberg SA., eds. Cancer: Principles & Practice of Oncology, 8th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 9.

    Frisch M, Glimelius B, van den Brule AJ. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:13501358.

  • 10.

    Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:15001510.

    • Search Google Scholar
    • Export Citation
  • 11.

    U.S. Statistics. HIV.gov Web site. Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Accessed August 16, 2017.

    • Search Google Scholar
    • Export Citation
  • 12.

    Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005;39:446453.

    • Search Google Scholar
    • Export Citation
  • 13.

    Chiao EY, Dezube BJ, Krown SE. Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304:334339.

  • 14.

    Branson BM, Handsfield HH, Lampe MA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:117; quiz CE1–4.

    • Search Google Scholar
    • Export Citation
  • 15.

    Bhuva NJ, Glynne-Jones R, Sonoda L. To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol 2012;23:20782082.

  • 16.

    Caldarella C, Annunziata S, Treglia G. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. Scientific World Journal 2014:196068.

    • Search Google Scholar
    • Export Citation
  • 17.

    Cotter SE, Grigsby PW, Siegel BA. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006;65:720725.

  • 18.

    Mistrangelo M, Pelosi E, Bello M. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 2012;84:6672.

    • Search Google Scholar
    • Export Citation
  • 19.

    Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw 2010;8:123129.

  • 20.

    Trautmann TG, Zuger JH. Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309313.

    • Search Google Scholar
    • Export Citation
  • 21.

    Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol 2017;90:20170370.

  • 22.

    Jones M, Hruby G, Solomon M. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:35743581.

    • Search Google Scholar
    • Export Citation
  • 23.

    Sekhar H, Zwahlen M, Trelle S. Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. Lancet Oncol 2017;18:13481359.

    • Search Google Scholar
    • Export Citation
  • 24.

    Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354356.

    • Search Google Scholar
    • Export Citation
  • 25.

    Cummings BJ, Keane TJ, O'Sullivan B. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21:11151125.

    • Search Google Scholar
    • Export Citation
  • 26.

    Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum 1992;35:422429.

    • Search Google Scholar
    • Export Citation
  • 27.

    Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist 2007;12:524534.

  • 28.

    Czito BG, Willett CG. Current management of anal canal cancer. Curr Oncol Rep 2009;11:186192.

  • 29.

    Glynne-Jones R, Lim F. Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 2011;79:12901301.

  • 30.

    Bartelink H, Roelofsen F, Eschwege F. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:20402049.

    • Search Google Scholar
    • Export Citation
  • 31.

    Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:10491054.

    • Search Google Scholar
    • Export Citation
  • 32.

    Northover J, Glynne-Jones R, Sebag-Montefiore D. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102:11231128.

    • Search Google Scholar
    • Export Citation
  • 33.

    Ajani JA, Winter KA, Gunderson LL. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:19141921.

    • Search Google Scholar
    • Export Citation
  • 34.

    Crehange G, Bosset M, Lorchel F. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum 2007;50:4349.

  • 35.

    Flam M, John M, Pajak TF. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:25272539.

    • Search Google Scholar
    • Export Citation
  • 36.

    Hofheinz RD, Wenz F, Post S. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579588.

    • Search Google Scholar
    • Export Citation
  • 37.

    O'Connell MJ, Colangelo LH, Beart RW. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:19271934.

    • Search Google Scholar
    • Export Citation
  • 38.

    Twelves C, Scheithauer W, McKendrick J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012;23:11901197.

    • Search Google Scholar
    • Export Citation
  • 39.

    Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:26962704.

  • 40.

    Glynne-Jones R, Meadows H, Wan S. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008;72:119126.

    • Search Google Scholar
    • Export Citation
  • 41.

    Goodman K, Rothenstein D, Lajhem C. Capecitabine plus mitomycin in patients undergoing definitive chemoradiation for anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2014;90:S32S33.

    • Search Google Scholar
    • Export Citation
  • 42.

    Meulendijks D, Dewit L, Tomasoa NB. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014;111:17261733.

    • Search Google Scholar
    • Export Citation
  • 43.

    Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiat Oncol 2014;9:124.

    • Search Google Scholar
    • Export Citation
  • 44.

    Oliveira SC, Moniz CM, Riechelmann R. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer 2016;47:7581.

    • Search Google Scholar
    • Export Citation
  • 45.

    James RD, Glynne-Jones R, Meadows HM. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 2013;14:516524.

    • Search Google Scholar
    • Export Citation
  • 46.

    Gunderson LL, Winter KA, Ajani JA. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012;30:43444351.

    • Search Google Scholar
    • Export Citation
  • 47.

    Eng C, Crane CH, Rodriguez-Bigas MA. Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? Nat Clin Pract Gastroenterol Hepatol 2009;6:1617.

    • Search Google Scholar
    • Export Citation
  • 48.

    Abbas A, Yang G, Fakih M. Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park) 2010;24:417424.

    • Search Google Scholar
    • Export Citation
  • 49.

    Peiffert D, Tournier-Rangeard L, Gerard JP. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012;30:19411948.

    • Search Google Scholar
    • Export Citation
  • 50.

    Spithoff K, Cummings B, Jonker D. Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. Clin Oncol (R Coll Radiol) 2014;26:473487.

    • Search Google Scholar
    • Export Citation
  • 51.

    Moureau-Zabotto L, Viret F, Giovaninni M. Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma? J Surg Oncol 2011;104:6671.

    • Search Google Scholar
    • Export Citation
  • 52.

    Sebag-Montefiore D, Meadows HM, Cunningham D. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Radiother Oncol 2012;104:155160.

    • Search Google Scholar
    • Export Citation
  • 53.

    Eng C, Chang GJ, Das P. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal [abstract]. J Clin Oncol 2009;27(suppl 15):Abstract 4116.

    • Search Google Scholar
    • Export Citation
  • 54.

    Cetuximab (Erbitux®) [package insert]. Branchburg, NJ: ImClone Systems Inc; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s262lbl.pdf. Accessed March 28, 2017.

    • Search Google Scholar
    • Export Citation
  • 55.

    Van Damme N, Deron P, Van Roy N. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010;10:189.

    • Search Google Scholar
    • Export Citation
  • 56.

    Zampino MG, Magni E, Sonzogni A, Renne G. K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol 2009;65:197199.

    • Search Google Scholar
    • Export Citation
  • 57.

    Garg M, Lee JY, Kachnic LA. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results [abstract]. J Clin Oncol 2012;30(suppl 15):Abstract 4030.

    • Search Google Scholar
    • Export Citation
  • 58.

    Garg MK, Zhao F, Sparano JA. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol 2017;35:718726.

    • Search Google Scholar
    • Export Citation
  • 59.

    Sparano JA, Lee JY, Palefsky J. Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial. J Clin Oncol 2017;35:727733.

    • Search Google Scholar
    • Export Citation
  • 60.

    Olivatto LO, Vieira FM, Pereira BV. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 2013;119:29732980.

    • Search Google Scholar
    • Export Citation
  • 61.

    Deutsch E, Lemanski C, Pignon JP. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013;24:28342838.

    • Search Google Scholar
    • Export Citation
  • 62.

    Levy A, Azria D, Pignon JP. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol 2015;114:415416.

    • Search Google Scholar
    • Export Citation
  • 63.

    Ortholan C, Ramaioli A, Peiffert D. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:479485.

    • Search Google Scholar
    • Export Citation
  • 64.

    Ferrigno R, Nakamura RA, Dos Santos Novaes PE. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 2005;61:11361142.

    • Search Google Scholar
    • Export Citation
  • 65.

    Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 2007;13:895900.

    • Search Google Scholar
    • Export Citation
  • 66.

    John M, Pajak T, Flam M. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996;2:205211.

    • Search Google Scholar
    • Export Citation
  • 67.

    Konski A, Garcia M Jr., John M. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114118.

    • Search Google Scholar
    • Export Citation
  • 68.

    Ben-Josef E, Moughan J, Ajani JA. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010;28:50615066.

    • Search Google Scholar
    • Export Citation
  • 69.

    Graf R, Wust P, Hildebrandt B. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003;65:1422.

    • Search Google Scholar
    • Export Citation
  • 70.

    Roohipour R, Patil S, Goodman KA. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008;51:147153.

    • Search Google Scholar
    • Export Citation
  • 71.

    Allal AS, Sprangers MA, Laurencet F. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999;80:15881594.

    • Search Google Scholar
    • Export Citation
  • 72.

    de Bree E, van Ruth S, Dewit LG, Zoetmulder FA. High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol 2007;14:100108.

    • Search Google Scholar
    • Export Citation
  • 73.

    Baxter NN, Habermann EB, Tepper JE. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005;294:25872593.

  • 74.

    Call JA, Prendergast BM, Jensen LG. Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. Am J Clin Oncol 2014;39:812.

    • Search Google Scholar
    • Export Citation
  • 75.

    Chen YJ, Liu A, Tsai PT. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 2005;63:274281.

    • Search Google Scholar
    • Export Citation
  • 76.

    Chuong MD, Freilich JM, Hoffe SE. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res 2013;6:3945.

    • Search Google Scholar
    • Export Citation
  • 77.

    DeFoe SG, Beriwal S, Jones H. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol) 2012;24:424431.

    • Search Google Scholar
    • Export Citation
  • 78.

    Franco P, Mistrangelo M, Arcadipane F. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Cancer Invest 2015;33:259266.

    • Search Google Scholar
    • Export Citation
  • 79.

    Kachnic LA, Tsai HK, Coen JJ. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012;82:153158.

    • Search Google Scholar
    • Export Citation
  • 80.

    Lin A, Ben-Josef E. Intensity-modulated radiation therapy for the treatment of anal cancer. Clin Colorectal Cancer 2007;6:716719.

  • 81.

    Milano MT, Jani AB, Farrey KJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354361.

    • Search Google Scholar
    • Export Citation
  • 82.

    Mitchell MP, Abboud M, Eng C. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 2014;37:461466.

    • Search Google Scholar
    • Export Citation
  • 83.

    Salama JK, Mell LK, Schomas DA. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007;25:45814586.

    • Search Google Scholar
    • Export Citation
  • 84.

    Yates A, Carroll S, Kneebone A. Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. Clin Oncol (R Coll Radiol) 2015;27:700707.

    • Search Google Scholar
    • Export Citation
  • 85.

    Bazan JG, Hara W, Hsu A. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011;117:33423351.

    • Search Google Scholar
    • Export Citation
  • 86.

    Dasgupta T, Rothenstein D, Chou JF. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol 2013;107:189194.

    • Search Google Scholar
    • Export Citation
  • 87.

    Kachnic LA, Winter K, Myerson RJ. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:2733.

    • Search Google Scholar
    • Export Citation
  • 88.

    Chin AL, Pollom EL, Qian Y. Impact of intensity-modulated radiotherapy on health care costs of patients with anal squamous cell carcinoma. J Oncol Pract 2017;13:e9921001.

    • Search Google Scholar
    • Export Citation
  • 89.

    Benson AB 3rd, Arnoletti JP, Bekaii-Saab T. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:449454.

    • Search Google Scholar
    • Export Citation
  • 90.

    Myerson RJ, Garofalo MC, El Naqa I. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824830.

    • Search Google Scholar
    • Export Citation
  • 91.

    Darragh TM, Colgan TJ, Cox JT. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136:12661297.

    • Search Google Scholar
    • Export Citation
  • 92.

    Arana R, Flejou JF, Si-Mohamed A. Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Dis 2015;17:965972.

    • Search Google Scholar
    • Export Citation
  • 93.

    Chai CY, Tran Cao HS, Awad S, Massarweh NN. Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg 2018;153:209215.

  • 94.

    Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:11201130.

    • Search Google Scholar
    • Export Citation
  • 95.

    Colon-Lopez V, Shiels MS, Machin M. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol 2018;36:6875.

  • 96.

    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:5967.

    • Search Google Scholar
    • Export Citation
  • 97.

    Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4:e495504.

    • Search Google Scholar
    • Export Citation
  • 98.

    Duncan KC, Chan KJ, Chiu CG. HAART slows progression to anal cancer in HIV-infected MSM. AIDS 2015;29:305311.

  • 99.

    Libois A, Feoli F, Nkuize M. Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study. Sex Transm Infect 2017;93:1517.

    • Search Google Scholar
    • Export Citation
  • 100.

    Piketty C, Selinger-Leneman H, Bouvier AM. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 2012;30:43604366.

    • Search Google Scholar
    • Export Citation
  • 101.

    Patel P, Hanson DL, Sullivan PS. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728736.

    • Search Google Scholar
    • Export Citation
  • 102.

    Grew D, Bitterman D, Leichman CG. HIV infection is associated with poor outcomes for patients with anal cancer in the highly active antiretroviral therapy era. Dis Colon Rectum 2015;58:11301136.

    • Search Google Scholar
    • Export Citation
  • 103.

    Oehler-Janne C, Huguet F, Provencher S. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008;26:25502557.

    • Search Google Scholar
    • Export Citation
  • 104.

    Alfa-Wali M, Dalla Pria A, Nelson M. Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol 2016;42:813816.

    • Search Google Scholar
    • Export Citation
  • 105.

    Bryant AK, Huynh-Le MP, Simpson DR. Association of HIV status with outcomes of anal squamous cell carcinoma in the era of highly active antiretroviral therapy. JAMA Oncol 2018;4:120122.

    • Search Google Scholar
    • Export Citation
  • 106.

    Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008;26:474479.

    • Search Google Scholar
    • Export Citation
  • 107.

    Leeds IL, Alturki H, Canner JK. Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World J Surg Oncol 2016;14:208.

    • Search Google Scholar
    • Export Citation
  • 108.

    Martin D, Balermpas P, Fokas E. Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy? Clin Oncol (R Coll Radiol) 2017;29:248255.

    • Search Google Scholar
    • Export Citation
  • 109.

    Pappou EP, Magruder JT, Fu T. Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: does HAART influence outcomes? World J Surg 2018;42:876883.

    • Search Google Scholar
    • Export Citation
  • 110.

    Seo Y, Kinsella MT, Reynolds HL. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009;75:143149.

    • Search Google Scholar
    • Export Citation
  • 111.

    White EC, Khodayari B, Erickson KT. Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal. Am J Clin Oncol 2014;40:386392.

    • Search Google Scholar
    • Export Citation
  • 112.

    Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 2015;33:23762383.

    • Search Google Scholar
    • Export Citation
  • 113.

    Faivre C, Rougier P, Ducreux M. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer 1999;86:861865.

    • Search Google Scholar
    • Export Citation
  • 114.

    Kole AJ, Stahl JM, Park HS. Predictors of nonadherence to NCCN guideline recommendations for the management of stage I anal canal cancer. J Natl Compr Canc Netw 2017;15:355362.

    • Search Google Scholar
    • Export Citation
  • 115.

    Geltzeiler CB, Tsikitis VL, Kim JS. Variation in the use of chemoradiotherapy for stage II and III anal cancer: analysis of the National Cancer Data Base. Ann Surg Oncol 2016;23:39343940.

    • Search Google Scholar
    • Export Citation
  • 116.

    Steele SR, Varma MG, Melton GB. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2012;55:735749.

  • 117.

    Cummings BJ. Metastatic anal cancer: the search for cure. Onkologie 2006;29:56.

  • 118.

    Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989;87:221224.

    • Search Google Scholar
    • Export Citation
  • 119.

    Eng C, Chang GJ, You YN. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 2014;5:1113311142.

    • Search Google Scholar
    • Export Citation
  • 120.

    Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol 1993;16:536540.

    • Search Google Scholar
    • Export Citation
  • 121.

    Kim S, Jary M, Mansi L. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol 2013;24:30453050.

    • Search Google Scholar
    • Export Citation
  • 122.

    Kim R, Byer J, Fulp WJ. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology 2014;87:125132.

  • 123.

    Sclafani F, Morano F, Cunningham D. Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients. Oncologist 2017;22:402408.

    • Search Google Scholar
    • Export Citation
  • 124.

    Matsunaga M, Miwa K, Oka Y. Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6 + bevacizumab. Case Rep Oncol 2016;9:249254.

    • Search Google Scholar
    • Export Citation
  • 125.

    Morris VK, Salem ME, Nimeiri H. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446453.

    • Search Google Scholar
    • Export Citation
  • 126.

    Ott PA, Piha-Paul SA, Munster P. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:10361041.

    • Search Google Scholar
    • Export Citation
  • 127.

    Salem ME, Puccini A, Grothey A. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res 2018;16:805812.

    • Search Google Scholar
    • Export Citation
  • 128.

    Glynne-Jones R, Sebag-Montefiore D, Meadows HM. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 2017;18:347356.

    • Search Google Scholar
    • Export Citation
  • 129.

    Schiller DE, Cummings BJ, Rai S. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 2007;14:27802789.

    • Search Google Scholar
    • Export Citation
  • 130.

    Mullen JT, Rodriguez-Bigas MA, Chang GJ. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 2007;14:478483.

    • Search Google Scholar
    • Export Citation
  • 131.

    Das P, Bhatia S, Eng C. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007;68:794800.

    • Search Google Scholar
    • Export Citation
  • 132.

    Sunesen KG, Norgaard M, Lundby L. Cause-specific colostomy rates after radiotherapy for anal cancer: a danish multicentre cohort study. J Clin Oncol 2011;29:35353540.

    • Search Google Scholar
    • Export Citation
  • 133.

    Ozsahin M, Santa Cruz O, Bouchaab H. Definitive organ-sparing treatment of anal canal cancer: can we afford to question it? J Clin Oncol 2012;30:673675.

    • Search Google Scholar
    • Export Citation
  • 134.

    Allal AS, Laurencet FM, Reymond MA. Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. Cancer 1999;86:405409.

    • Search Google Scholar
    • Export Citation
  • 135.

    Delhorme JB, Severac F, Waissi W. Surgery is an effective option after failure of chemoradiation in cancers of the anal canal and anal margin. Oncology 2017;93:183190.

    • Search Google Scholar
    • Export Citation
  • 136.

    Ellenhorn JD, Enker WE, Quan SH. Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus. Ann Surg Oncol 1994;1:105110.

    • Search Google Scholar
    • Export Citation
  • 137.

    Nilsson PJ, Svensson C, Goldman S, Glimelius B. Salvage abdominoperineal resection in anal epidermoid cancer. Br J Surg 2002;89:14251429.

  • 138.

    Wright JL, Gollub MJ, Weiser MR. Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal. Dis Colon Rectum 2011;54:10901097.

    • Search Google Scholar
    • Export Citation
  • 139.

    Chessin DB, Hartley J, Cohen AM. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol 2005;12:104110.

    • Search Google Scholar
    • Export Citation
  • 140.

    Devulapalli C, Jia Wei AT, DiBiagio JR. Primary versus flap closure of perineal defects following oncologic resection: a systematic review and meta-analysis. Plast Reconstr Surg 2016;137:16021613.

    • Search Google Scholar
    • Export Citation
  • 141.

    Lefevre JH, Corte H, Tiret E. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol 2012;19:41864192.

    • Search Google Scholar
    • Export Citation
  • 142.

    Harris DA, Williamson J, Davies M. Outcome of salvage surgery for anal squamous cell carcinoma. Colorectal Dis 2013;15:968973.

  • 143.

    Hewitt M, Greenfield S, Stovall E, eds. From cancer patient to cancer survivor: lost in transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council: National Academy of Sciences; 2006. Available at: http://georgiacore.org/articleImages/articlePDF_396.pdf. Accessed June 22, 2018.

    • Search Google Scholar
    • Export Citation
  • 144.

    El-Shami K, Oeffinger KC, Erb NL. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 2015;65:428455.

  • 145.

    Bentzen AG, Guren MG, Vonen B. Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiother Oncol 2013;108:5560.

    • Search Google Scholar
    • Export Citation
  • 146.

    Mirabeau-Beale K, Hong TS, Niemierko A. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol 2015;5:e113118.

    • Search Google Scholar
    • Export Citation
  • 147.

    Sunesen KG, Norgaard M, Lundby L. Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for anal cancer: a Danish multicentre cross-sectional questionnaire study. Colorectal Dis 2015;17:O230239.

    • Search Google Scholar
    • Export Citation
  • 148.

    Knowles G, Haigh R, McLean C, Phillips H. Late effects and quality of life after chemo-radiation for the treatment of anal cancer. Eur J Oncol Nurs 2015;19:479485.

    • Search Google Scholar
    • Export Citation
  • 149.

    Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004;16:530535.

    • Search Google Scholar
    • Export Citation
  • 150.

    Badin S, Iqbal A, Sikder M, Chang VT. Persistent pain in anal cancer survivors. J Cancer Surviv 2008;2:7983.

All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 4941 3436 278
PDF Downloads 1463 1007 86
EPUB Downloads 0 0 0